News

Celladon’s drugs act upon the Sarcoplasmic Reticulum ATPase2a (SERCA2a) pump, the central control point for progression of heart failure. Treatments targeting this pathway essentially reversed the deterioration in

Phase I small business innovation research grant was awarded to Neurion by the National Institute of Mental Health (NIMH). Dr Paul Bennett, Neurion’s vice president of discovery, said:

The blood-brain barrier is the system of capillary endothelial cells that protects the brain from harmful substances in the blood stream. It is this cell wall that also

The companies are investigating an unconfirmed report of a Tysabri patient with symptoms consistent with progressive multifocal leukoencephalopathy (PML), a rare brain disease. Of the three previous patients

O24 fibromyalgia pain reliever will become the first product to carry the National Fibromyalgia Association (NFA) official seal of approval on its packaging. It will be sold over-the-counter,

The Committee for Orphan Medicinal Products (COMP) at the European Agency recommended orphan status for the anticancer monoclonal antibody 1D09C3. The orphan drug status would become effective following

HuMax-CD20 is capable of attacking more targets expressing low levels of CD20, a molecule implicated in lymphoid tumors, than rituximab. When low levels of CD20 are present on

Xenical (orlistat) was found to be significantly more effective than diet alone in reducing weight and improving cardiovascular risk factors in overweight patients or those suffering from obesity.

The collaboration centers on the production of ANA975 and additional Toll-Like Receptor 7 (TLR7) oral prodrugs for the treatment of infectious disease. Under the exclusive global license and